Page 2 - பார்மா உயிர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பார்மா உயிர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பார்மா உயிர் Today - Breaking & Trending Today

Nicox: Half-year liquidity contract statement with Kepler

-        Number of executions on sell side on semester: 609
-        Traded volume on buy side on semester: 457,955 shares for € 1,916,480.01
-        Traded volume on sell side on semester: 310,810 shares for € 1,312,111.94
•        the following resources appeared on the liquidity account when the activity started:
-        0 shares
-        € 500,000.00
The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.
About Nicox
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formu ....

New York , United States , Provence Alpes Côd Azur , France General , United Kingdom , City Of , Victor Floc H , Gavin Spencer , Yi Chen , Damien Choplain , Pharma Bio , Mary Ann Chang , Pooya Hemami , Sophia Antipolis , Sophie Baumont , Louise Chen , Kepler Cheuvreux , States Europe , Head Of Corporate Development , Edison Investment Research , Lifesci Advisors , Cantor Fitzgerald , Garnier Co , Eyevance Pharmaceuticals , Hc Wainwright Co , Ocumension Therapeutics ,

Nicox: Half-year liquidity contract statement with Kepler Cheuvreux

Nicox: Half-year liquidity contract statement with Kepler Cheuvreux
July 6, 2021 - release at 7:30 am CET
Sophia Antipolis, France
Under the liquidity contract entered into between NICOX and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2021:
- 218,919 shares
- Number of executions on sell side on semester: 1,298
- Traded volume on buy side on semester: 978,682 shares for € 4,245,529.01
- Traded volume on sell side on semester: 906,908 shares for € 3,977,929.37
As a reminder :
• the following resources appeared on the last half year statement on 31 December 2020 on the liquidity account:
- 147,145 shares
- Number of executions on sell side on semester: 609 ....

New York , United States , Provence Alpes Côd Azur , France General , United Kingdom , Gavin Spencer , Pharma Bio , Kepler Cheuvreux Damien Choplain , Mary Ann Chang , Sophia Antipolis , Sophie Baumont , Cantor Fitzgerald Louise Chen , Kepler Cheuvreux , States Europe , Garnier Co Victor Floch Paris , Head Of Corporate Development , Lifesci Advisors , Eyevance Pharmaceuticals , Edison Investment Research Pooya Hemami London , Ocumension Therapeutics , Southeast Asian , Euronext Paris , Mid Caps , Victor Floc H , Louise Chen , Investment Research ,

Nicox to Receive $2 Million from Ocumension Therapeutics as

® Agreement
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize ZERVIATE
® (cetirizine ophthalmic solution), 0.24% in the Chinese and the majority of South East Asian markets. Under the amended agreement, Ocumension will immediately pay Nicox $2 million in full advance payment of the future development and regulatory milestones for the product. Amendments were made to certain rights under non-financial clauses of the agreement.
Nicox remains eligible to receive the same sales milestones of up to US$17.2 million together with tiered royalties of between 5% and 9% of net sales of ZERVIATE by Ocumension. ZERVIATE is currently being evaluated in a confirmatory Phase 3 clinical trial in China by Ocumension, to support a Chinese New Drug App ....

New York , United States , Provence Alpes Côd Azur , France General , United Kingdom , South Korea , City Of , Victor Floc H , Gavin Spencer , Yi Chen , Damien Choplain , Pharma Bio , Mary Ann Chang , Pooya Hemami , Sophia Antipolis , Sophie Baumont , Louise Chen , Kepler Cheuvreux , States Europe , Lifesci Advisors , Garnier Co , Head Of Corporate Development , Edison Investment Research , Cantor Fitzgerald , Eyevance Pharmaceuticals , Hc Wainwright Co ,

Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial

Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial
July 2nd, 2021 - release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase as well as the required two-week follow up period. Top-line results are expected to be announced in September 2021.

Mississippi trial
Phase 2
at Nicox,
amount
used to guide the future development of
NCX 4251
.
We will announce the next steps in the development of NCX 4251 following an End-of-Phase 2 meeting with the FDA. ....

New York , United States , Provence Alpes Côd Azur , France General , United Kingdom , Gavin Spencer , Pharma Bio , Kepler Cheuvreux Damien Choplain , Mary Ann Chang , Sophia Antipolis , Sophie Baumont , Cantor Fitzgerald Louise Chen , States Europe , Garnier Co Victor Floch Paris , Head Of Corporate Development , Lifesci Advisors , Eyevance Pharmaceuticals , Edison Investment Research Pooya Hemami London , Euronext Paris , Interim Head , Ocumension Therapeutics , Southeast Asian , Mid Caps , Victor Floc H , Louise Chen , Investment Research ,

Nicox's NCX 470 Demonstrates Significant Intraocular

Nicox's NCX 470 Demonstrates Significant Intraocular
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

New York , United States , Provence Alpes Côd Azur , France General , United Kingdom , City Of , Victor Floc H , Gavin Spencer , Yi Chen , David Wirta , Damien Choplain , Pharma Bio , Mary Ann Chang , Pooya Hemami , Mont Blanc , Sophia Antipolis , Sophie Baumont , Louise Chen , Kepler Cheuvreux , States Europe , Allergan Inc , Lifesci Advisors , Garnier Co , World Glaucoma Congress , Head Of Corporate Development , Edison Investment Research ,